For the first time in a decade, body mass index and obesity prevalence in adults declined in the United States in 2023.

Arkansas was the first state to start sending letters home flagging students' Body Mass Index. Twenty years later, they do not appear to have had any effect on childhood obesity.

Despite the rising competition in the obesity space, we believe that there is room for smaller biotechs like Viking Therapeutics to grab a share of this booming market.

Adult obesity rates in the United States dropped from 46% in 2022 to 45.6% in 2023, according to the new study published in ...

(HealthDay News) — The mean body mass index (BMI) and prevalence of obesity declined in the United States in 2023, according to research published in JAMA Health Forum.

“Most of the evidence suggests that the effect size of these interventions should be small and universal across states ... a ...

Novo Nordisk NVO shares have plunged 17.9% in a week due to poorer-than-expected efficacy data from a late-stage study of its ...

Pfizer's oncology promises are several years from being actualized. Read why investors shouldn't assume that a sustained ...

MONDAY, Dec. 23, 2024 (HealthDay News) — Body mass index (BMI) and obesity prevalence declined in the United States in 2023, according to a research letter published online Dec. 13 in JAMA Health ...

Stock market today: Nasdaq hits record high as major earnings from big tech loom By Investing.com - Oct 29, 2024 30 Investing.com -- The Nasdaq closed at record highs Tuesday, shrugging off mixed ...

Eli Lilly and Company LLY announced that the FDA has approved its popular obesity drug ... has also filed regulatory applications in the United States and EU to seek approval for tirzepatide ...